Company

Orakl Oncology SAS

Orakl Oncology develops data-driven tools for personalized cancer treatment and drug development.

About

Orakl Oncology is a France-based company combining technology, biology, and artificial intelligence for cancer treatment and drug development. Its platform uses tumor models that mimic drug responses alongside clinical and omics data. CEO Fanny Jaulin co-founded the company with Diane-Laure Pagès and Gustave Ronteix. It raised EUR 3 million in October 2023 and EUR 11 million in seed funding in December 2024.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in